IPO queue bulges further as Adagene, NexImmune are among latest to file

After a record year for NASDAQ listings, a burgeoning queue of biopharmas seeking IPOs in 2021 swelled further late Tuesday as immuno-oncology companies Adagene and NexImmune filed for offerings.

The pair joined seven therapeutics developers that filed late Friday, as well as a handful of others that submitted prospectuses earlier this month. The flow of biotechs into the queue has shown no signs of abating in the early months of 2021, with only a brief holiday lull separating this year’s crop from the 65 biopharmas that raised at least $50 million in IPOs on NASDAQ last year...